Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Oct 23 - Oct 28
Interestingly, Lilly is not only accelerating by adding this kind of a strong third pillar of global growth next to the U.S
Published January, 2023
Neuroprotective effects could be especially important in treating neurodegenerative diseases such as Parkinson's disease or Alzheimer's disease
p = 0.026 for superiority) ( p = 0.067)
Quick Comparison Feature CagriSema Retatrutide Development owner Novo Nordisk Eli Lilly Core strategy Combination therapy Single-molecule multi-agonist Pathways Amylin + GLP-1 GIP + GLP-1 + glucagon Main components Cagrilintide + semaglutide Retatrutide (LY3437943) 2026 status Phase 3 / regulatory-watch candidate Phase 3 TRIUMPH program Best-fit research question Can amylin extend GLP-1 results
US$ 20.37
US$ 23.43
US$ 25.15
US$ 24.13
US$ 29.33
US$ 20.22
US$ 21.81
US$ 21.55
US$ 23.33
